CRISPR

gene-editing-treatment.jpg
First Gene-Editing Treatment Injected Into the Blood Reduces Toxic Protein for up to 1 Year
The first team to disable a disease gene directly in a person through an infusion of the genome editor CRISPR reported yesterday that levels of the toxic protein…
Read more
intellia-therapeutics-logo.png
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome…
Read more
INTELLIA_LOGO-01.png
Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based…
Read more
Doherty_CRISPR.jpg
He Inherited A Devastating Disease. A CRISPR Gene-Editing Breakthrough Stopped It
Patrick Doherty had always been very active. He trekked the Himalayas and hiked trails in Spain. But about a year and a half ago, he noticed pins and needles in his…
Read more
Subscribe to